Pomalidomide for Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib (TA427)

Technology Appraisal Guidance No. 427

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Pomalidomide, in combination with low-dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib, only when the company provides pomalidomide with the discount agreed in the patient access scheme.

1.2 This guidance is not intended to affect the position of patients whose treatment with pomalidomide was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at www.nice.org.uk/guidance/ta427

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib

Issue Date: January 2017

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Insulin Delivery Devices

Insulin Delivery Devices

Features and compatibility of insulin pens.

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Don't treat subclinical hypothyroidism, prescribers advised

Don't treat subclinical hypothyroidism, prescribers advised

GPs should monitor patients with subclinical hypothyroidism...

Refresh your knowledge on prescribing in pregnancy with MIMS Learning

Refresh your knowledge on prescribing in pregnancy with MIMS Learning

MIMS Learning is offering a new interactive module,...